We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Patients with poorly controlled type 2 ...

Results presented at the American Diabetes Association in June showed no CV risk or benefit and no risk of pancreatic injury, an issue that has been of particular concern to FDA. FDA has accepted a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults with type 2 diabetes, established cardiovascular ...

Results first presented at the American Diabetes Association in June are published. The new drug application has since been filed at FDA. Results from the ELIXA trial, which showed that the GLP-1 ...

PARIS -- Sanofi announced today the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia® (lixisenatide) in adults with ...

PARIS, France, June 9, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today data demonstrating Lyxumia®* (lixisenatide), a once-daily investigational GLP-1 agonist, in combination ...

radiographic image of kidneys Lixisenatide reduces progression of urinary albumin-creatinine ratio in patients with macroalbuminuria. HealthDay News — For patients with type 2 diabetes and acute ...

(HealthDay News) — The addition of lixisenatide to usual care does not impact the rate of major cardiovascular events or other serious adverse events among patients with type 2 diabetes and a recent ...

Patients with early Parkinson disease who received lixisenatide had a decrease in motor disability progression, but they also experienced gastrointestinal side effects. Lixisenatide vs placebo is ...

BOSTON (updated June 9) — Lixisenatide (Lyxumia, Sanofi), an injectable glucagonlike peptide (GLP-1) agonist used for the treatment of type 2 diabetes, did not show a benefit on cardiovascular ...

The European Commission has granted approval of lixisenatide (Lyxumia, Sanofi) for the treatment of adults with type 2 diabetes mellitus. The drug, a once-daily glucagonlike peptide 1 (GLP-1) agonist, ...